Evidence map›Paper›PMID 32992014›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.

Hiroyuki Takoi, Yuki Togashi, Daiki Fujimori, Haruki Kaizuka, Shunsuke Otsuki, Takuya Wada, Yoshikazu Takeuchi, Shinji Abe

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Pooled it
  2. Drug fever: a narrative review.Annals of clinical epidemiology · 2023
    Article
  3. Article
  4. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  5. Article
  6. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.Chembiochem : a European journal of chemical biology · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hiroyuki TakoiDepartment of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: taco155485@hotmail.com.
Yuki TogashiDepartment of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: togashiy@tokyo-med.ac.jp.
Daiki FujimoriDepartment of Rheumatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: fujimorifugusashifugufugu@yahoo.co.jp.
Haruki KaizukaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: fj0e.h.k@gmail.com.
Shunsuke OtsukiDepartment of Hematology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: i4112356@gmail.com.
Takuya WadaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: wwwtk0820@yahoo.co.jp.
Yoshikazu TakeuchiDepartment of Cardiology and Division of Preemptive Medicine for Vascular Damage, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: yoshi.c603@gmail.com.
Shinji AbeDepartment of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: sabe@tokyo-med.ac.jp.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptoms of COVID-19. No other cause for fever was evident after careful physical examination and laboratory investigation. The fever subsided in both patients after the discontinuation of favipiravir. To the best of our knowledge, this is the first report of favipiravir-induced fever in COVID-19 patients.

Indexed as

COVID-19 Drug TreatmentAdultAmidesAntiviral AgentsBody TemperatureCOVID-19Drug-Related Side Effects and Adverse ReactionsFemaleFeverHumansMalePyrazinesSARS-CoV-2Treatment OutcomeAmidesAntiviral AgentsfavipiravirPyrazinesCOVID-19Drug feverFavipiravir

Identifiers

PMID32992014
PMCPMC7521433
OpenAlexW3088180073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.